As of 2025-12-30, the Relative Valuation of GT Biopharma Inc (GTBP) is (27.01) USD. This relative valuation is based on P/E multiples. With the latest stock price at 0.83 USD, the upside of GT Biopharma Inc based on Relative Valuation is -3345.2%.
The range of the Relative Valuation is (24.09) - (26.42) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 19.5x - 24.1x | 21.8x |
| Forward P/E multiples | 22.0x - 32.9x | 27.4x |
| Fair Price | (24.09) - (26.42) | (27.01) |
| Upside | -2994.0% - -3273.4% | -3345.2% |
| Date | P/E |
| 2025-12-26 | -0.76 |
| 2025-12-24 | -0.77 |
| 2025-12-23 | -0.73 |
| 2025-12-22 | -0.71 |
| 2025-12-19 | -0.69 |
| 2025-12-18 | -0.67 |
| 2025-12-17 | -0.64 |
| 2025-12-16 | -0.66 |
| 2025-12-15 | -0.57 |
| 2025-12-12 | -0.60 |
| 2025-12-11 | -0.59 |
| 2025-12-10 | -0.61 |
| 2025-12-09 | -0.58 |
| 2025-12-08 | -0.59 |
| 2025-12-05 | -0.56 |
| 2025-12-04 | -0.57 |
| 2025-12-03 | -0.55 |
| 2025-12-02 | -0.69 |
| 2025-12-01 | -0.71 |
| 2025-11-28 | -0.72 |
| 2025-11-26 | -0.73 |
| 2025-11-25 | -0.68 |
| 2025-11-24 | -0.69 |
| 2025-11-21 | -0.67 |
| 2025-11-20 | -0.64 |
| 2025-11-19 | -0.62 |
| 2025-11-18 | -0.60 |
| 2025-11-17 | -0.63 |
| 2025-11-14 | -0.84 |
| 2025-11-13 | -0.67 |
| 2025-11-12 | -0.66 |
| 2025-11-11 | -0.62 |
| 2025-11-10 | -0.60 |
| 2025-11-07 | -0.56 |
| 2025-11-06 | -0.50 |
| 2025-11-05 | -0.56 |
| 2025-11-04 | -0.56 |
| 2025-11-03 | -0.57 |
| 2025-10-31 | -0.57 |
| 2025-10-30 | -0.57 |
| 2025-10-29 | -0.54 |
| 2025-10-28 | -0.61 |
| 2025-10-27 | -0.63 |
| 2025-10-24 | -0.62 |
| 2025-10-23 | -0.67 |
| 2025-10-22 | -0.61 |
| 2025-10-21 | -0.64 |
| 2025-10-20 | -0.67 |
| 2025-10-17 | -0.63 |
| 2025-10-16 | -0.62 |